Earnings call transcript: Teva’s Q2 2026 revenue beats, shares rise premarket By Investing.com
Teva Pharmaceutical reported Q2 2026 revenue of $4.14B, above the $4.05B consensus, and raised full-year 2026 revenue guidance by $75M at the midpoint. Reported non-GAAP EPS was $0.02 vs about $0.62 expected, largely due to a $724M Emalex acquisition charge. Teva shares rose 5.84% premarket to $33.52.
How this was made
The 30-second read
Why it matters
The key tradable update is the combination of a Q2 revenue beat, raised full-year 2026 revenue guidance, and product-level guidance increases, which the market appears to be pricing despite a reported EPS miss driven by an Emalex-related charge.
Market read
Investors are reacting to raised sales outlook and innovative-portfolio momentum, which may dominate near-term sentiment versus one-time acquisition charges.
What to watch
Generics revenue fell 15% due to loss of Revlimid contribution, and the Emalex-related charge may complicate future comparisons even if adjusted EPS looks better.
Background
Teva is in a “Pivot to Growth” strategy, shifting from legacy generics toward an innovative portfolio (AUSTEDO, AJOVY, UZEDY) and biosimilars.
Ticker impact
Teva reported Q2 revenue of $4.14B above consensus and raised full-year 2026 revenue guidance, driving a 5.84% premarket stock gain despite an EPS miss.
Near-term upside bias likely persists while investors focus on raised revenue outlook and product-specific guidance (AUSTEDO, AJOVY, UZEDY).
The article cites a revenue beat, explicit guidance increase of $75M at the midpoint, and product-level raises, while attributing the large EPS miss to a one-time acquisition-related expense.
Market effects
Reinforces the market narrative that branded/innovative pharma mix can stabilize earnings quality even when legacy generics face pressure.
Primarily US-listed pharma sentiment; rate-hike jitters are cited as a headwind for the broader tape.
Limited beyond large-cap pharma read-through, since the catalyst is company-specific guidance and product performance.
Counterpoint
The EPS miss is large in absolute terms, and elevated operating expenses plus inventory dynamics (AUSTEDO) could pressure margins and cash conversion later.
Key entities
- companyTeva Pharmaceutical Industries
Reported Q2 revenue beat, raised 2026 revenue guidance, and provided product-level outlook for AUSTEDO, AJOVY, and UZEDY.
- companyEmalex Biosciences
Acquisition-related charge tied to Emalex is cited as the main driver of the reported EPS miss.
- productAUSTEDO
Management raised full-year 2026 guidance midpoint to $2.45B to $2.6B.
- productAJOVY
Management raised full-year 2026 guidance midpoint to $850M to $870M.
- productUZEDY
Management raised full-year 2026 guidance midpoint to $270M to $290M.
